Posted by Michael Wonder on 21 Dec 2017
Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance
20 December 2017 - Multiple sclerosis drug, Extavia, has been approved for routine funding on the NHS, in NICE draft guidance.
A discount to the price of this drug now means it can be recommended as a cost effective option for adults with relapsing- remitting multiple sclerosis (MS) or secondary progressive MS with continued relapses.
Affecting around 116,000 people in England, MS is a chronic and disabling condition affecting the brain and spinal cord.
